𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer

✍ Scribed by Yeu-Tsu N. Lee; Frank C. Sparks; Frederick R. Eilber; Dr. Donald L. Morton

Publisher
John Wiley and Sons
Year
1975
Tongue
English
Weight
580 KB
Volume
35
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Delayed cutaneous hypersensitivity, lymp
Delayed cutaneous hypersensitivity, lymphocyte count, and blood tests in patients with breast carcinoma
✍ Yeu-Tsu N.(Margaret) Lee πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 587 KB

General immunocompetence was examined in 125 patients with various stages of breast cancer. Tests include peripheral blood lymphocyte count, serum protein electrophoresis, quantitative immunoglobulins, CEA level, and delayed cutaneous hypersensitivity (DCH) reaction to six recall antigens (PPD, Moni

Peripheral B- and T-lymphocyte counts in
Peripheral B- and T-lymphocyte counts in patients with sarcoma and breast carcinoma
✍ Yeu-Tsu N. Lee; G. June Marshall; John Weiner; Joseph R. Bateman πŸ“‚ Article πŸ“… 1977 πŸ› John Wiley and Sons 🌐 English βš– 434 KB πŸ‘ 2 views

Peripheral B- and T-lymphocyte counts were studied in 50 patients before they received any therapy for their conditions: 16 had carcinoma of the breast; 8 soft tissue sarcoma; and 26, benign disease. Among 11 males, the six patients with advanced soft tissue sarcoma had significantly lower percentag

Specific and aspecific immune responsive
Specific and aspecific immune responsiveness in lung cancer patients: Cutaneous delayed hypersensitivity reactions to a lung cancer-associated antigen
✍ Ercole Sega; Marcella Mottolese; Paola Cordiali-Fei; Gennaro Citro; Sergio Coliz πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 English βš– 661 KB

## Abstract The ability of a lung cancer‐associated antigen (LCAA) to provoke specific cutaneous delayed‐hypersensitivity reactions has been studied on a group of 59 lung cancer patients. Biological activity of LCAA, monitored by skin testing, was demonstrated in 32% (17 of 53) of lung cancer patie